Fischer Lena, Imrich Eike, Sampaio Kerstin Laib, Hofmann Jörg, Jahn Gerhard, Hamprecht Klaus, Göhring Katharina
Institute of Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, 72076 Tübingen, Germany.
Institute of Virology, University Hospital Ulm, 89081 Ulm, Germany.
Antiviral Res. 2016 Jul;131:1-8. doi: 10.1016/j.antiviral.2016.04.002. Epub 2016 Apr 4.
Human cytomegalovirus (HCMV) drug-resistance remains of high clinical importance. While UL97-mutations can confer ganciclovir-resistance, UL54-mutations can be associated with resistance to ganciclovir, foscarnet and/or cidofovir.
Three UL97-mutations (A619V, P468Q, del597-599), three UL54-mutations (V715A, A492D, L516W) and two UL97/UL54-mutation combinations (A594TUL97+V715MUL54; A591VUL97+D515EUL54, L516MUL54, I521TUL54) were characterised phenotypically. All mutations were introduced into the bacterial artificial chromosome (BAC) TB40-BACKL7-UL32EGFP. A revertant of HCMV-TB40-BACKL7-UL32EGFP/A591VUL97+D515EUL54, L516MUL54, I521TUL54 was generated.
The UL97-mutation del597-599 showed GCV-resistance while A619V and P468Q were drug-sensitive. The UL54-mutation V715A was FOS-resistant/CDV-hypersensitive and L516W was GCV/CDV cross-resistant. Mutation A594TUL97+V715MUL54 showed GCV/FOS cross-resistance. HCMV-BACKL7-UL32EGFP/A591VUL97+D515EUL54,L516MUL54, I521TUL54 was GCV/CDV cross-resistant with a remarkably increased GCV-ratio compared to a strain where only the UL54-mutations D515E+L516M+I521T were present. Since the revertant was drug-sensitive again, the increased drug-ratio is supposed to be due to the UL97-polymorphism A591V.
Phenotypic characterisation of newly detected mutations in UL97 and UL54 remain of high importance. Only mutations with a confirmed phenotype allow reliable interpretation of genotypic methods. Here, we provide the first description of a UL97-polymorphism that contributes to the overall drug-resistance when combined with resistance-associated UL54-mutations. The finding shows the high importance to look at mutations in the context of their genetic background.
人巨细胞病毒(HCMV)耐药性在临床上仍具有高度重要性。虽然UL97突变可导致对更昔洛韦耐药,但UL54突变可能与对更昔洛韦、膦甲酸钠和/或西多福韦的耐药性有关。
对三个UL97突变(A619V、P468Q、del597 - 599)、三个UL54突变(V715A、A492D、L516W)以及两个UL97/UL54突变组合(A594T UL97 + V715M UL54;A591V UL97 + D515E UL54、L516M UL54、I521T UL54)进行表型特征分析。将所有突变导入细菌人工染色体(BAC)TB40 - BACKL7 - UL32EGFP。构建了HCMV - TB40 - BACKL7 - UL32EGFP/A591V UL97 + D515E UL54、L516M UL54、I521T UL54的回复株。
UL97突变del597 - 599表现出对更昔洛韦耐药,而A619V和P468Q对药物敏感。UL54突变V715A对膦甲酸钠耐药/对西多福韦超敏,L516W对更昔洛韦/西多福韦交叉耐药。突变A594T UL97 + V715M UL54表现出对更昔洛韦/膦甲酸钠交叉耐药。HCMV - BACKL7 - UL32EGFP/A591V UL97 + D515E UL54、L516M UL54、I521T UL54对更昔洛韦/西多福韦交叉耐药,与仅存在UL54突变D515E + L516M + I521T的菌株相比,其更昔洛韦比值显著增加。由于回复株再次对药物敏感,推测增加的药物比值归因于UL97多态性A591V。
对UL97和UL54中新检测到的突变进行表型特征分析仍然非常重要。只有具有确定表型的突变才能可靠地解释基因分型方法。在此,我们首次描述了一种UL97多态性,当与耐药相关的UL54突变结合时,它会导致整体耐药性。这一发现表明在基因背景中研究突变具有高度重要性。